INTRODUCTION
GW bodies (GWBs) are cytoplasmic foci in mammalian cells, initially recognized by human autoimmune sera and are enriched with a marker protein GW182, which is characterized by multiple glycine (G) and tryptophan (W) repeats and a carboxyl terminal classical RNA-binding domain 1 . GWBs are thought to be the sites responsible for messenger RNA (mRNA) processing and degradation 2, 3 and provide the appropriate microenvironment for the RNAinduced silencing complex (RISC) and critical steps in the RNA interference (RNAi) pathway 4, 5 . GW182 has been shown to colocalize with mRNA decay factors Dcp1 and LSm4 in mammalian cells 6 , and accordingly, GWB are thought to be closely related or identical to processing bodies (P-bodies) that are involved in mRNA storage and decay in Saccharomyces cerevisiae 2, 3 . A number of additional proteins that localize to GWBs have subsequently been described and they include the deadenylase Ccr4, 5¢-decapping factor Dcp2, exonuclease XRN1, rck/p54 and the LSm1-7 complex (reviewed in refs. 3, [7] [8] [9] . GWBs may also participate in other mechanisms of mRNA expression control given that GWBs contain the cap-binding protein eIF4E and the related factor eIF4E-transporter (eIF4E-T) 10, 11 . The interaction between these two factors represses mRNA translation and is thought to serve as a prerequisite for the targeting of mRNA to GWB for degradation 10, 11 . Of paramount interest, GWBs contain RNAi pathway components 4, 5 , including Dicer, Ago2 and microRNAs (miRNA), that are incorporated in the effector complex RISC (reviewed in refs. 3, 8, 12, 13) , ultimately leading to either cleavage or translational inhibition of the target mRNA. Finally, stress granules are shown to be dependent on and share components with GWBs (see refs. 14,15). Stress granules have been shown to be composed of nontranslating mRNAs that interact with GWBs and may 'hand off' mRNAs to GWBs where they are targeted for repression and/or degradation [16] [17] [18] [19] [20] .
Historically, many laboratories have had difficulties in identifying GW182 and related GWB proteins by conventional western blot (WB), a challenge that may be attributed to a number of features that include their molecular mass, relatively low abundance and/or incompletely understood unique physicochemical properties, such as the high-density hydrophobic glycine(G)/tryptophan(W) domains 1 . Before examining the biochemical interactions between GW182 and other messenger ribonucleoprotein components as outlined in this protocol, indirect immunofluorescence and colocalization studies are commonly used as a first step to determine whether a protein of interest is located in spatial proximity to GW182/GWB. This paper is focused on GW182 and details a protocol to aid in identifying the diverse functions of GWB, but as discussed below, it can be adapted or suitably modified to study a variety of cellular components such as neuronal granules, RNA granules, messenger ribonucleoprotein and other RNA-binding protein complexes. This protocol first immunoprecipitates the protein complex of interest from the cellular milieu using GWB antibodies covalently coupled to Protein A or G sepharose beads, followed by WB to detect proteins of interest associated with the cognate protein complex of interest (Fig. 1) . First, an antibody showing high specificity for the low-abundance target (i.e., GW182) is coupled to a solid-phase matrix (Protein A or G sepharose beads); this then binds protein(s) of interest and adsorbs the protein complex from the cell lysates. Other proteins not bound to the antibody-Protein A or G bead support are washed away and the proteins of interest are eluted from the antibody-coupled beads and separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). This is followed by WB to determine the identity of proteins that are associated with the protein of interest. An important advantage of combined immunoprecipitation (IP)-WB reactions over WB alone is their potential to deliver not only the target protein but also other macromolecules that interact with the target protein. The IP-WB protocol published previously by our group 21, 22 that used human polyclonal sera to detect other proteins associated with RISC, P-bodies and mRNA granules has been modified by adopting the use of monoclonal antibodies raised against GW182 and other key components of GWB (reviewed in ref. 8) . Although monoclonal antibodies are probes of choice, they may have limitations in biochemical techniques that can be attributed to low-affinity polyreactivity (particularly IgM antibodies), low concentrations in commercially available preparations and reactivity to restricted epitopes that may be inaccessible when proteins retain their tertiary structures.
As indicated above, this protocol can most likely be adapted and modified to detect other RNA-binding proteins and mRNA complexes that can lead to a further understanding of the role of GWB components in RNA interference 8 , mRNA stabilization and transport 3, 21 and cell stress responses 18 . These analyses include RT-PCR, which examine interactions of RNA-binding proteins with their cognate mRNAs 23 , or cDNA arrays, which examine large-scale RNA-binding protein mRNAs 24 . In addition, this protocol has been adapted to identify mRNAs and miRNAs associated with GW182 in miRNA microarrays as when total RNA was extracted from IPs and analyzed in a protocol that used a monoclonal Ago2 antibody to identify the associated miRNAs by RT-PCR 25 .
Experimental design Sample type and preparation. This method was first published using U-87 astrocytoma cells 21 and more recently HeLa cells 22 , but it can be applied to other cell types according to the user's preference. Protein isolated from tissues may be examined using the methodology outlined in this protocol but has not been examined by the authors. Cell morphology, growth patterns and resulting cell density are well known to differ between cell lines. For example, when examining the difference between HeLa cells and U-87 astrocytoma cells, it is obvious that the latter cells have long, widely spread projections that are remarkably different from the much more compact phenotype seen in HeLa cell cultures. This type of growth pattern, typical of astrocytoma cells, requires a larger number of U-87 cells to obtain the same amount of protein harvested from HeLa cells. It is very important to appreciate that a relatively large amount of protein (B40 mg per lane) is recommended to identify the GW182-associated proteins or other lowabundance proteins. Cell lysis in this protocol is achieved by mechanical methods without the addition of salts or detergents. From experience, mechanical methods for the detection of GW182 are superior to the use of lytic or chaotropic agents. Addition of lysis buffers containing detergents and salts may interfere with native protein conformation, protein-protein interactions and the binding of proteins to antibodies in the subsequent IP. Both lysis approaches must be tested and optimized for particular cells and tissues that may be used in other studies. Comparison of lysis methods are made following IP and WB steps and the choice ultimately rests with the investigator.
Choice of antibodies for IP and WB.
First, an important consideration is the choice of antibodies used to immunoprecipitate the protein complex of interest. The chosen antibodies should have proven specificity and minimal cross-reactivity or nonspecific binding. Human serum 18033 was initially used to immunoprecipitate GW182 (see refs. 21, 22) , but the results have recently been improved with the use of the commercially available mouse monoclonal 4B6 antibody. Human 18033 serum is polyclonal, recognizes multiple GWB-associated proteins, such as GW182, Ago2 and Rap55, and efficiently immunoprecipitates GWBassociated proteins and detects GW182 by WB (Fig. 2) . Mouse monoclonal 4B6 was generated by immunization with recombinant GW182 (see ref. 26 ) and it can be used to immunoprecipitate GW182 from the cytoplasmic protein milieu and to detect GW182 and Ago2 by WB (Fig. 2a,c) . As cross-reactivity tends to be more common when polyclonal antibodies are used or when low-avidity IgM monoclonal antibodies are used, it is very important to select antibodies of the highest specificity and affinity for the protein in question. Hence, it is important to test the specificity and binding characteristics of different antibodies in a pilot IP analysis to validate their efficiency and usefulness. For WB analysis, antibodies should be proven acceptable for WB applications, be specific for the protein of interest and their dilution must be optimized to achieve a result that produces low background reactions.
Control antibodies. Control antibodies must be chosen for IP and WB that do not cross-react with the proteins of interest (i.e., GW182) but are specific for their cognate antigen. For example, mouse monoclonal golgin 97 (CDF4) antibody is specific to the Golgi complex golgin 97 protein (Fig. 2d , extract lane, protein band at B97 kDa) but does not bind to GW182 or associate with GWB complex proteins (Fig. 2d , 18033 IP lane) in WB analysis. Another example is IC6 human serum, which contains antibodies that recognize the Ge-1/Hedls protein (Fig. 2a,c Figure 2 | Antibodies to GW182-immunoprecipitated Ago2, Dicer and XRN1 proteins from HeLa cell extracts as examined by WB analysis. GW182 and associated proteins were immunoprecipitated using human sera 18033 containing antibodies to GW182 coupled with Protein A sepharose beads and by mouse anti-GW182 monoclonal 4B6 coupled to Protein G sepharose beads. Normal human serum (NHS), IC6 human serum and mouse monoclonal antibody to golgin 97 were used as IP controls. Immunopreciptates were carried out with buffer that did not contain detergent. Proteins (40 mg) were resolved on a 10% SDS-PAGE gel and were detected with a 4B6 monoclonal antibody (a) or 18033 human anti-GWB serum (b). Immunopreciptates were carried out with buffer that contained 0.3% NP-40 detergent. Proteins (40 mg) were resolved on a 6.5% SDS-PAGE gel and were detected using a mouse anti-Ago2 monoclonal 4F9 antibody (c). Protein (40 mg) from whole cell extracts or 18033 immunoprecipitates carried out using 0.3% NP-40 buffer were separated on a 6.5% SDS-PAGE gel and probed with NHS or antibodies to golgin 97, GW182, Ago2, XRN1 or Dicer. (d) Mouse monoclonal antibody to Dicer and rabbit anti-XRN1 antibody were purchased from Abcam Inc. (cat. no. ab14601) and Bethyl Laboratories (cat. no. A300-443A), respectively. Mouse monoclonal 4F9 to recombinant hAgo2 was obtained as described previously 25 .
Membrane choice and transfer. Nitrocellulose membranes are used in this protocol but polyvinylidene fluoride membranes may be used; however, they have not been extensively tested by the authors. Wet transfers at 22-25 V (overnight, 4 1C) have worked best for transfer of proteins from SDS-PAGE (6.5%, 10% or 12% (vol/vol) gel), although semidry transfer has also been used with some success (unpublished data).
MATERIALS

REAGENTS
. Cells of choice approximately 1 Â 10 9 -1 Â 10 11 cells (B20 T-150 cm 2 U-87 cell flasks to yield 12 mg ml À1 protein and B10 T-150 cm 2 HeLa cell flasks to yield 20 mg ml À1 protein)
. . Spectrophotometer of choice with 1.5-ml disposable cuvettes (VWR, cat. no.
97000-586)
. ! CAUTION Acrylamide is a suspected human carcinogen and a severe neurotoxin and causes irritation of the eyes, skin (is readily absorbed) and respiratory tract. Wear gloves, lab coat, safety lab goggles and keep the bottle pointed away from the user when transferring liquid. ! CAUTION SDS is highly flammable, harmful in contact with skin and irritant to the respiratory tract and eyes. Wear suitable protective clothing, gloves and a mask covering the mouth and nose. ! CAUTION TEMED is corrosive, highly flammable and harmful by inhalation. Wear suitable protective clothing, gloves and eye/face protection. Mix the top five reagents in a 50-ml centrifuge tube or Erlenmeyer flask to obtain the gel percentage of choice. The components of the 5% (vol/vol) stacking gel are combined in another 50-ml centrifuge tube or Erlenmeyer flask. Add 10% (wt/vol) APS and TEMED to the other reagents immediately before pouring the gel liquid into the gel apparatus. After pouring the resolving gel, layer the top with water-saturated butanol or water. Leave the gel to solidify for 45 min to 1 h. If using water-saturated butanol, rinse the gel surface with ddH 2 O five times. Add 10% (wt/vol) APS and TEMED to stacking gel mixture and pour on top of the resolving gel. Position combs and let the gel solidify for 45 min to 1 h. Transfer buffer Combine 23.2 g of Tris base, 11.6 g of glycine, 1.48 g of SDS and 800 ml of methanol, and add ddH 2 O up to 4 liters. Store at room temperature for a maximum of 3 months. Ponceau S stain Prepare 0.5% (wt/vol) Ponceau Red and 1% (vol/vol) glacial acetic acid in ddH 2 O. May be reused several times. Store at room temperature indefinitely. 5% (wt/vol) skimmed milk in PBST Dissolve 5.0 g of skimmed milk powder in 100 ml of PBST. Use immediately or store at 4 1C for up to 2 d. Stripping buffer Prepare 2% (wt/vol) SDS, 62.5 mM Tris, pH 6.7, and 100 mM 2-mercaptoethanol in PBST in the fume hood. Store at room temperature for a maximum of 1 year without the addition of 2-mercaptoethanol. Use immediately after the addition of 2-mercaptoethanol. 3| Discard the supernatant and add 5 ml of ice-cold sterile protease-free PBS to each 50-ml tube. Resuspend the pellets and pool into one 15-ml tube.
4| Repeat
Step 2 and wash with an additional 5 ml aliquot of ice-cold sterile protease-free PBS.
5| Repeat
Step 2 and discard the supernatant. Add an equal pellet volume of ice-cold sterile protease-free PBS with protease inhibitor (B850 ml) to the cell pellet, resuspend the cells and place on ice.
6| Sonicate the cells in the water bath sonicator for 80 s, vortex and place the cells on ice. Repeat after 1 min.
7| Shear the viscous lysate by passing four times through a syringe fitted with a 21 G 1.5-inch needle. m CRITICAL STEP Using mechanical lysis with 21 G 1.5-inch needle is critical.
8|
Transfer the lysate to a 1.5-ml microfuge tube. Centrifuge the lysate in a tabletop microfuge for 10 min at 16,000g and 4 1C. Collect the supernatant into a new 1.5-ml microfuge tube and place on ice.
9| Quantitate the concentration of protein extract in the sample using either the colorimetric BCA protein assay following the manufacturer's instructions with a spectrophotometer set at 562 nm using bovine serum albumin as standards or the Nanodrop 1,000. The concentration of the protein extract is typically 12-15 mg ml À1 . ' PAUSE POINT Store the lysate at À20 or À70 1C for short-term (up to 1 week) or long-term (up to 1 year) use, respectively. ? TROUBLESHOOTING Equilibration of sepharose beads TIMING Overnight 10| Prepare a 10% (wt/vol) Protein A sepharose slurry by washing 0.75 g of Protein A beads two times with 10 ml of sterile PBS with protease inhibitor. Equilibrate Protein A beads in 25 ml of sterile PBS containing protease inhibitor. Allow the beads to swell overnight at 4 1C to prepare for day 2.
11| Protein G sepharose beads are supplied in ethanol. Transfer 5 ml of beads stored in 70% (vol/vol) ethanol to a 50-ml centrifuge tube. Centrifuge the beads at 196g for 5 min at room temperature and discard the supernatant. Wash a total of five times with 20 ml of sterile PBS to remove all traces of ethanol. Prepare a 10% (wt/vol) Protein G sepharose slurry by adding 25 ml of sterile PBS containing protease inhibitor to the washed Protein G beads. Allow the beads to swell overnight at 4 1C to prepare for day 2.
Day 2: covalent coupling of antibodies to Protein A or G using DMP TIMING 5.5 h up to pause point; after pause point (Step 34), allow for an additional 4 h 12| Transfer 2 ml of the 10% (wt/vol) suspension of Protein A sepharose beads into two 15-ml centrifuge tubes. Add 150 ml of normal human serum (NHS control) to the bead slurry in one tube and 150 ml of the human serum 18033 to the other tube.
13| Transfer 2 ml of 10% (wt/vol) suspension of Protein G sepharose beads into two 15-ml centrifuge tubes. Add 500 ml of mouse monoclonal golgin 97/CDF4 antibody control to the bead slurry in one tube and 500 ml of mouse monoclonal 4B6 antibody to the other tube.
14| Allow the antibodies to bind to the beads (from Steps 12 and 13) for 2 h at room temperature on a rolling (nutating) mixer.
15| Add 5 ml of SBB to each antibody-bound bead slurry.
16| Centrifuge for 1 min at low speed (196g) at room temperature to pellet the beads; discard the supernatant.
17| Wash the beads once using 5 ml of SBB, centrifuge as in Step 16 and discard the supernatant. 18| To determine if the coupling procedure is successful, resuspend the beads (B200 ml packed bead volume) in 200 ml of SBB to achieve a 50% (wt/vol) bead suspension. Remove a 10 ml aliquot of the beads and label as 'Before Sample' . Add 10 ml of 2Â LSB to this aliquot, mix and store at À20 1C until the coupling procedure is complete.
19| Centrifuge the remaining 50% (wt/vol) bead suspension as in Step 16 and discard the supernatant.
20| Dissolve solid DMP in SBB (see REAGENT SETUP) and add 5 ml to each 15-ml tube of beads. m CRITICAL STEP DMP must be prepared in SBB immediately before use because of its instability in solution.
21| Mix the beads by placing the 15-ml tubes on a rolling mixer for 1 h at room temperature.
22| Centrifuge for 1 min at 196g at room temperature to pellet the beads and discard the supernatant.
23| Add 1 ml of 0.2 M ethanolamine, pH 8.0, and mix gently. 26| Add 5 ml of ethanolamine and incubate for 2 h at room temperature on a rolling mixer.
27| Centrifuge for 1 min at 196g at room temperature to pellet the beads and discard the supernatant.
28| Add 2 ml of sterile PBS and mix gently.
29| Centrifuge for 1 min at 196g at room temperature and discard the supernatant.
30| Repeat Steps 28 and 29.
31| Resuspend the beads (B200 ml packed bead volume) in 200 ml of sterile PBS to achieve a 50% (wt/vol) bead suspension. Remove a 10-ml aliquot of beads and label as 'After Sample' . Add 10 ml of 2Â LSB to this aliquot, mix and store at À20 1C.
32| Using the remaining 50% (wt/vol) bead solution, repeat Step 29.
33| Add 1 ml of sterile PBS with protease inhibitor to each 15-ml tube to achieve a 20% (wt/vol) suspension of beads. ' PAUSE POINT Store beads at 4 1C for up to 1 year. For long-term storage, add 0.05% (wt/vol) sodium azide to prevent bacterial contamination. After storage in sodium azide, the beads should be washed three times with sterile PBS and resuspended in sterile PBS with protease inhibitor before use.
34| Check the success of the antibody coupling to the beads by analyzing the 'Before' and 'After' samples using 10% (vol/vol) SDS-PAGE (see REAGENT SETUP). Boil the samples at 95 1C for 5 min and load carefully into wells along with a protein ladder of interest. Separate the proteins with 120 V until the blue bands migrate to the bottom of the gel. Stain the gel with Colloidal Blue Staining Kit as per the manufacturer's instructions and leave in ddH 2 O overnight to destain the background (see Fig. 3 for an example of successful covalent coupling of antibodies to sepharose beads). ? TROUBLESHOOTING Day 3: preclearing protein extracts and immunoprecipitation TIMING o o o o3.5 h 35| Thaw the protein extract from day 1 (Step 9) on ice and divide into two 1.5-ml microcentrifuge tubes (200 ml to each tube). Label tubes 'Protein A extract' and 'Protein G extract' . Save B50 ml of protein extract to use as a 'no IP extract control' on day 4 (Step 43). Protein extracts have a protein concentration of B12 mg ml À1 ; therefore, each tube of 400 ml contains 2,400 mg of protein.
36|
To preclear the extract, add 50 ml of 10% (wt/vol) Protein A sepharose beads in sterile PBS with protease inhibitors (prepared in Step 10) to 'Protein A extract' and 50 ml of 10% (wt/vol) Protein G sepharose beads in sterile PBS with protease inhibitors (prepared in Step 11) to 'Protein G extract' . Incubate on a rotator for 30 min up to 1 h at 4 1C. Alternatively, incubate on a rotator at room temperature for 5-10 min.
37| Centrifuge for 1 min at 82g at room temperature with a microcentrifuge and remove the precleared extract into a clean 1.5-ml tube to use for IP. Step
39| Centrifuge the tubes for 1 min at 82g at room temperature to collect the beads and discard the supernatant.
40| Wash the beads with 1 ml of ice-cold NET2F by rotating the tubes for 5 min at 4 1C. Centrifuge for 1 min at 82g at room temperature to collect the beads and discard the supernatant. Wash the beads for a total of five times. m CRITICAL STEP If using a NET2F buffer with a high salt concentration (i.e., 500 mM), wash four times with the same NET2F buffer and wash an additional two times with a NET2F buffer that contains a lower salt concentration (i.e., 150 mM). IPs that are carried out and washed with higher salt concentrations will alter the expected protein migration.
41| After the last wash, pellet the beads by centrifugation at 82g for 1 min at room temperature and discard the supernatant. Add an equal volume of 2Â LSB to the bead volume (approximately 20-25 ml). ' PAUSE POINT Store IPs with 2Â LSB at À20 1C overnight or proceed right away to SDS-PAGE described on day 4. Prepared gels may also be stored overnight at 4 1C wrapped in moist paper towel and saran wrap. Day 5: detecting GW182, other RISC components or mRNA degradation proteins by WB analysis TIMING 5+ h 48| Remove the membrane from the overnight wet transfer and wash briefly in ddH 2 O. Stain membranes briefly (B1 min) with Ponceau S stain on a rocking platform shaker and destain with quick washes with ddH 2 O until proteins bands are pink and the background is nearly white. Dry the membrane at room temperature on a filter paper. Label the membrane as needed. ' PAUSE POINT Store the membrane at À20 1C until required between two sheets of filter paper and wrapped in tin foil, or proceed with WB. ? TROUBLESHOOTING 49| Block the nitrocellulose membrane for 1 h at room temperature in 5% (wt/vol) nonfat milk in PBST.
50| Overlay the membrane with the primary antibody of choice at the appropriate dilution in 5% (wt/vol) milk/PBST for 1 h at room temperature. Recommended dilutions for WB using the same antibodies used in the IP, which include 4B6 (1:2 up to 1:10), 18033 (1:1,000), NHS (1:500) and golgin 97 (1:200).
51| Wash the membrane with PBST three times, for 10 min each, on a rocking platform shaker.
52| Overlay the membrane with secondary HRP-conjugated antibodies of choice at their appropriate dilution in 5% (wt/vol) milk/PBST for 1 h at room temperature. Although this may vary from laboratory to laboratory, suggested dilutions for secondary HRP antibodies (see REAGENTS) are goat anti-human (1:20,000) and goat anti-mouse (1:2,000).
53| Repeat
Step 51.
54| Detect bound antibody using ECL reagents (mixed in a 1:1 ratio) for 1 min. Remove excess ECL reagent and place in film cassette. 
55|
In the dark room, expose the film to the membrane for the desired length of time (start at 1 min up to a maximum of 15 min depending upon the type of film used). Develop in an automated film developer or in developing reagents (fixer and developer). ? TROUBLESHOOTING 56| To reuse membranes, wash them with three changes of PBST for 10 min each. Strip antibodies from antigens using stripping buffer (see REAGENT SETUP) for 45 min at 50 1C to allow reprobing using different antibodies in further WB analysis. Wash three times for 10 min with PBST and store in fresh PBST at 4 1C.
TIMING
Steps 1-9, day 1, cell lysate preparation: 2.5 h Steps 10 and 11, day 1, equilibration of sepharose beads: overnight Steps 12-34, day 2, covalent coupling of antibodies to Protein A or G using DMP: 9. 
ANTICIPATED RESULTS
The yield of protein from day 1 depends upon the volume of lysis buffer, cell type used and the growth pattern of the cell line. In general, approximately 1 Â 10 9 À1 Â 10 11 cells should be harvested to yield 12-20 mg of protein. Before IP, the success of the coupling procedure should be examined by resolving 'Before' coupling and 'After' coupling antibody-bead samples in 10% (vol/vol) SDS-PAGE (see example in Fig. 3 ). The antibody light and heavy chains should be visible on the gel in the 'Before' sample, but not in the 'After' sample, as the covalently coupled antibodies should remain bound to the beads after boiling in 2Â LSB (Fig. 3) . Ponceau S staining of nitrocellulose membranes after protein transfer should produce red or pink stained bands (Fig. 4) . If the protein of interest is associated with GWB, optimal results would appear as clean, sharp bands in the 4B6 and 18033 IP lanes, with no bands present in the golgin 97, NHS and IC6 IP control lanes. Cell lysate extracts with no IP serve as a control to ensure that the antibody recognizing the protein of interest is working properly by WB analysis (Fig. 2d, lanes). Figure 2 shows a variety of typical IP-WBs using HeLa cells to examine the proteins associated with GWB. The antibodies were used as described by Moser et al. 21 . Figure 2a shows the detection of the 182-kDa GW182 by WB with monoclonal antibody 4B6 in the 18033 and 4B6 IPs but not in the control IPs (NHS, IC6 and golgin 97). This shows that commercially available 4B6 can be used effectively to IP GW182 and detect it by WB. The additional lower molecular weight bands observed with the 4B6 IP (Fig. 2a) is unexplained at this time but may be related to the observation that 4B6 binds to an epitope 26 that is not shared by human anti-GWB sera tested to date 27 . Figure 2b shows the detection of GW182 at 182 kDa by WB with 18033 serum (contains autoantibodies directed to GWB) in the 18033 IP but not in the control NHS IP. This confirms that 18033 antiserum contains GW182 antibodies. Figure 2c shows the detection of Ago2 (the catalytic effector protein of the RISC) at B95 kDa by WB analysis in GW182 IPs (18033 and 4B6) but not in the control IPs (NHS, IC6, golgin 97). This confirms previous observations that Ago2 is associated with GW182 (see refs. [28] [29] [30] [31] [32] [33] [34] and the apparent enrichment of Ago2 in the 18033 IP lane as compared with the 4B6 IP lane is due to the binding of 18033 to the Ago2 protein. Figure 2d shows that GWB contain proteins GW182, Ago2, XRN1 (exonuclease involved in 5¢-3¢ mRNA degradation) and Dicer (double-stranded RNA-specific endonuclease involved in RNAi). GW182 and Ago2 were enriched in the 18033 IP as compared with the cellular extract (4B6 and Ago2 WB), whereas XRN1 and Dicer were enriched in the cellular extract as compared with the 18033 IPs (XRN1 and Dicer WB). As expected, the 97-kDa golgin 97 protein was present in the extract but not in the 18033 IP. As indicated, control NHS is not expected to react with 18033 IP or the cellular extract. 
